<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Urinary Tract Tumors</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

      <h1>Urinary Tract Tumors</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        <br>
        <br>

        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>

          <ul>
              <li><b>Tumours of the urinary tract</b> can be benign or malignant.</li>
              <li><b>Solid tumours</b> are malignant until otherwise proven.</li>
              <li><b>Tumours of the LUT</b> are more common than UUT tumours.</li>
              <li>Most are <b>asymptomatic</b> commonly.</li>
              <li>The presence of <b>symptoms</b> heralds advanced disease.</li>
              <li>Management is <b>multidisciplinary</b>.</li>
              <li>Aim and modalities of management depend on the <b>stage</b>.</li>
              <li>Prognosis is guarded and dependent on many factors.</li>
          </ul>
          

                      <!-- image here -->
                      <div class="image-container">
                        <img src="../figures/urinary-tract-tumors (1).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Urinary Tract Anatomy</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Urinary Tract Anatomy</div>
                      </div>
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Renal Tumours</a>
          </h2>
        </header>
        <div class='body'>

          <h4>Renal Tumours</h4>

          <ul>
              <li><b>85%</b> are malignant.</li>
              <li>May arise from any of the tissue components of the kidney.</li>
              <li>Most common malignant tumour is <b>RCC</b>.</li>
          </ul>
          
          <h4>Benign</h4>
          <ul>
              <li><b>Metanephric Adenoma</b></li>
              <li><b>Oncocytoma</b></li>
              <li><b>Angiomyolipoma</b></li>
              <li><b>Leiomyoma</b></li>
              <li><b>Lipoma</b></li>
              <li><b>Fibroma</b></li>
              <li><b>Rhabdomyoma</b></li>
              <li><b>Neurofibroma</b></li>
              <li><b>Hemangioma</b></li>
          </ul>
          
          <h4>Malignant</h4>
          <ul>
              <li><b>Paediatric</b></li>
              <ul>
                  <li><b>Wilm‚Äôs Tumour</b></li>
              </ul>
              <li><b>Adult</b></li>
              <ul>
                  <li><b>RCC</b></li>
                  <li><b>Transitional cell Carcinoma</b></li>
                  <li><b>Squamous cell Carcinoma</b></li>
                  <li><b>Sarcoma</b></li>
                  <li><b>Lymphomas</b></li>
                  <li><b>Hemangiopericytomas</b></li>
                  <li><b>Malignant fibrous histiocytomas</b></li>
              </ul>
          </ul>
          
          
          <section id='heading-2-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-1'>Renal Cell Carcinoma</a>
              </h3>
            </header>
            <div class='body'>

              <ul>
                  <li>Arises from <b>renal tubular cells</b></li>
                  <li><b>2-3%</b> of all adulthood cancers</li>
                  <li><b>40%</b> of patients die of cancer</li>
                  <li>Most common in the <b>6th and 7th decade</b></li>
                  <li><b>M:F</b> is <b>2:1</b></li>
              </ul>
              
              <h4>Aetiology</h4>
              <ul>
                  <li><b>Multifactorial</b></li>
                  <li>Majority of cases are sporadic, <b>NCI reported 4%</b> as familial</li>
                  <li><b>Life style, environmental,</b> and <b>genetic predispositions</b> identified</li>
              </ul>
              
              <h4>Risk Factors</h4>
              <ul>
                  <li><b>Cigarette smoking</b></li>
                  <li><b>Obesity</b></li>
                  <li><b>Hypertension</b></li>
                  <li>Medications - <b>diuretics, phenacetin</b></li>
                  <li>Preexisting renal conditions - <b>stones, cysts, infections</b></li>
                  <li><b>Diabetes Mellitus</b></li>
                  <li><b>Reproductive and hormonal factors</b></li>
                  <li><b>Physical activities</b></li>
                  <li><b>Diet and beverages</b></li>
                  <li><b>Occupation</b></li>
                  <li><b>Genetic</b></li>
              </ul>
              
              <h4>Pathology: Histologic Types/Classification of RCC</h4>
              <ul>
                  <li><b>Clear Cell RCC</b></li>
                  <li><b>Papillary RCC</b></li>
                  <li><b>Chromophobe RCC</b></li>
                  <li><b>Oncocytomas</b></li>
                  <li><b>Collecting Duct Carcinoma</b></li>
              </ul>
              
              <h4>Pathology: Staging- TNM Staging System</h4>
              <ul>
                  <li>By <b>AJCC & IUCC</b></li>
                  <li>Most widely used for staging all variants</li>
                  <li>Correlates very well with prognosis</li>
                  <li>Revised in <b>2010</b></li>
                  <li>Tumors limited to the kidney are classified as <b>T1 or T2</b> based on the size</li>
                  <li><b>T3 tumors</b> extend into the renal vein or perinephric tissues but not beyond Gerota‚Äôs fascia</li>
                  <li><b>T4 tumors</b> extend beyond Gerota‚Äôs fascia</li>
                  <li>Node & distant metastases are simply classified as absent or present</li>
              </ul>
              
                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/urinary-tract-tumors (1).png" alt="" onclick="openModal(this)">
              <div class="caption"> TNM Staging System</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">TNM Staging System</div>
            </div>


              <h4>Clinical Presentations</h4>

              <ul>
                  <li><b>Asymptomatic</b> in >50%</li>
                  <li>Incidental diagnosis on <b>imaging studies</b></li>
                  <li><b>25%</b> at presentation have advanced locoregional or metastatic disease</li>
                  <li>
                      <b>1/3rd</b> of patients post-surgery for localized disease will relapse
                      <ul>
                          <li>Symptoms could be <b>local or systemic</b></li>
                      </ul>
                  </li>
                  <li>Classic triad of <b>flank pain, mass,</b> and <b>haematuria</b> occur in <b><10%</b></li>
                  <li><b>Varicocele</b> ‚Äì left (11%)</li>
                  <li><b>IVC involvement</b></li>
                  <li><b>Non-specific symptoms</b></li>
              </ul>
              

              <h4>Investigation</h4>

              <ul>
                  <li><b>Angiography</b>
                      <ul>
                          <li>Generally supplanted by <b>MRI Angiography</b></li>
                          <li>Used for preoperative tumor embolization</li>
                      </ul>
                  </li>
                  <li><b>IVU</b>
                      <ul>
                          <li>Indicated for haematuria</li>
                          <li>Lacks sensitivity and specificity for detection of parenchymal renal lesion</li>
                      </ul>
                  </li>
                  <li><b>MRI</b>
                      <ul>
                          <li>Superior to CT for evaluation of <b>IVC involvement</b></li>
                          <li>Useful when <b>USS & CT</b> are nondiagnostic or in cases of <b>contrast allergy or renal impairment</b></li>
                      </ul>
                  </li>
                  <li><b>FNAC/Biopsy</b>
                      <ul>
                          <li>Generally not done</li>
                      </ul>
                  </li>
                  <li><b>Chest X-ray/Chest CT</b></li>
                  <li><b>FBC</b></li>
                  <li><b>BUE + Cr</b></li>
                  <li><b>Urinalysis</b></li>
                  <li><b>LFT</b></li>
                  <li><b>Serum ALP</b></li>
                  <li><b>etc</b></li>
              </ul>
              

              <h4>Treatment</h4>

              <ul>
                  <li><b>Surgery</b> is the mainstay of treatment</li>
                  <li>However, there are other available options</li>
                  <li>What is done is dependent on the clinicopathologic stage at presentation as:</li>
                  <ul>
                      <li><b>Localised disease</b></li>
                      <li><b>Locally advanced disease</b></li>
                      <li><b>Metastatic disease</b></li>
                  </ul>
              </ul>
              
              <h4>Treatment Modalities</h4>
              <ul>
                  <li><b>Surgery</b>
                      <ul>
                          <li>Open</li>
                          <li>Laparoscopic</li>
                          <li>Ablative</li>
                      </ul>
                  </li>
                  <li><b>Hormonal therapy</b></li>
                  <li><b>Immunotherapy</b></li>
                  <li><b>Targeted Therapy</b></li>
                  <li><b>Combination therapy</b></li>
              </ul>
              
              <h4>Radical Nephrectomy</h4>
              <ul>
                  <li>Open or laparoscopic</li>
                  <li>No evidence to favor specific approach</li>
                  <li>Suitable for localized disease</li>
              </ul>
              
              <h4>Indications for Open Radical Nephrectomy</h4>
              <ul>
                  <li>Large tumor with regional adenopathy</li>
                  <li>Involvement of IVC or right atrial extension</li>
                  <li>Metastatic RCC for cytoreductive nephrectomy</li>
                  <li>Where partial nephrectomy is no longer possible</li>
              </ul>
              
              <h4>Follow-up After Nephrectomy</h4>
              <ul>
                  <li>This is to determine presence of recurrence and the need for additional therapy</li>
                  <li>Risk for recurrence:
                      <ul>
                          <li>7% T‚ÇÅN‚ÇÄM‚ÇÄ</li>
                          <li>20% T‚ÇÇN‚ÇÄM‚ÇÄ</li>
                          <li>40% T‚ÇÉN‚ÇÄM‚ÇÄ</li>
                      </ul>
                  </li>
                  <li>6-monthly clinical assessment</li>
                  <li>Annual CT scan for 3-10 years</li>
                  <li>Surgical excision is preferred choice</li>
              </ul>
              

              <h4>Locally Advanced RCC</h4>
              <ul>
                  <li>Disease involving IVC, right atrium, liver, bowel, or posterior abdominal wall</li>
                  <li>An aggressive surgical approach ‚Äì multidisciplinary surgical team</li>
              </ul>
              
              <h4>Adjuvant Therapy</h4>
              <ul>
                  <li>Immunotherapy</li>
                  <li>Targeted Therapy</li>
                  <li>Radiotherapy</li>
              </ul>
              
              <h4>Metastatic RCC</h4>
              <ul>
                  <li>Approximately <b>25%</b> of patients with RCC have metastasis at presentation</li>
                  <li><b>30%</b> of other patients progress to this stage after nephrectomy</li>
                  <li>Prognosis is generally poor</li>
                  <li>There is improved prognosis in patients with:
                      <ul>
                          <li>Good performance status</li>
                          <li>Tumor nephrectomy</li>
                          <li>Single organ solitary metastasis</li>
                          <li>Absence of tumor thrombus</li>
                      </ul>
                  </li>
              </ul>
              
              <h4>Prognosis</h4>
              <ul>
                  <li>Pathologic stage</li>
                  <li>Nuclear grade</li>
                  <li>Histologic subtype</li>
                  <li>Tumor size</li>
                  <li>Systemic symptoms</li>
                  <li>Metastatic burden</li>
                  <li>Performance status</li>
              </ul>
              
            </div>
          </section>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Bladder Tumour</a>
          </h2>
        </header>
        <div class='body'>

          <ul>
              <li>Bladder cancer is the second most common malignancy of the urogenital tract after prostate cancer in Nigeria</li>
              <li>It represents <b>7%</b> of all cancers and <b>3%</b> of all cancer deaths</li>
              <li>It is the <b>7th</b> most common cancer worldwide</li>
              <li>Mortality in Egypt is higher than in Europe</li>
              <li><b>Smoking</b> and <b>occupational exposure to carcinogens</b> are significant risk factors</li>
          </ul>
          
                      <!-- image here -->
                      <div class="image-container">
                        <img src="../figures/urinary-tract-tumors (2).jpg" alt="" onclick="openModal(this)">
                        <div class="caption">Relevant anatomy</div>
                      </div>
                      
                      <div id="myModal" class="modal">
                        <span class="close" onclick="closeModal()">&times;</span>
                        <img class="modal-content" id="modalImage">
                        <div id="caption" class="caption">Relevant anatomy</div>
                      </div>


                      <h4>Risk Factors</h4>

                      <ul>
                          <li><b>Smoking.</b></li>
                          <li><b>Age.</b></li>
                          <li>Chronic inflammation of the bladder:
                              <ul>
                                  <li><b>S. hematobium,</b> HPV, chronic UTI, bladder stones.</li>
                              </ul>
                          </li>
                          <li><b>Genetic:</b> HRAS, KRAS2, RB1, FGFR3, P2RY5</li>
                          <li><b>Irradiation;</b></li>
                          <li><b>Environmental:</b> nuclear plants</li>
                          <li><b>Therapeutic exposures:</b> treatment of other cancers.</li>
                          <li><b>Chemical exposure;</b></li>
                          <li>
                              Aniline dyes
                              <ul>
                                  <li>Aromatic amines (naphthylamine, amino-phenyl benzidine)</li>
                                  <li>Arsenic-contaminated or chlorinated water and drinks.</li>
                                  <li>Artificial sweeteners.</li>
                                  <li>Cyclophosphamide.</li>
                              </ul>
                          </li>
                          <li><b>Family history.</b></li>
                          <li>
                              <b>Occupation;</b> mechanics, hair-dressers, printers, painters.
                          </li>
                          <li><b>Dietary factors.</b></li>
                      </ul>

                      <h4>Pathological Types</h4>

                      <p><b>In terms of gross appearance:</b></p>
                      <ul>
                          <li><b>Papillary (70%)</b></li>
                          <li><b>Nodular (10%)</b></li>
                          <li><b>Mixed (20%)</b></li>
                      </ul>
                      
                      <p><b>In terms of histological appearance:</b></p>
                      <ul>
                          <li><b>Transitional Cell Carcinoma (90%)</b></li>
                          <li><b>Squamous Cell Carcinoma (5%)</b></li>
                          <li><b>Adenocarcinoma (0.5-2%)</b></li>
                          <li><b>Small Cell Carcinoma (rare)</b></li>
                          <li><b>Lymphoma, Sarcoma & Carcinosarcoma, etc.</b></li>
                      </ul>
                      

                      <div class="tips-card">
                        <p class="tips-card-subtitle">note</p>
                        <h4 class="tips-card-title">
                          TNM staging
                        </h4>
                        <p class="tips-card-content">
                          <h4>Primary tumour (T): urinary bladder</h4>
                          <ul>
                            <li><strong>TX</strong>: Primary tumour cannot be assessed</li>
                            <li><strong>T0</strong>: No evidence of primary tumour</li>
                            <li><strong>Ta</strong>: Papillary non-invasive carcinoma</li>
                            <li><strong>Tis</strong>: Carcinoma in situ: "flat tumour"</li>
                            <li><strong>T1</strong>: Tumour invades subepithelial connective tissue</li>
                            <li><strong>T2</strong>: Tumour invades muscle</li>
                            <li><strong>T2a</strong>: Tumour invades superficial muscle (inner half)</li>
                            <li><strong>T2b</strong>: Tumour invades deep muscle (outer half)</li>
                            <li><strong>T3</strong>: Tumour invades perivesical tissue</li>
                            <li><strong>T3a</strong>: Microscopically</li>
                            <li><strong>T3b</strong>: Macroscopically (extravesical mass)</li>
                            <li><strong>T4</strong>: Tumour invades any of the following: prostate, uterus, vagina, pelvic wall and abdominal wall</li>
                            <li><strong>T4a</strong>: Tumour invades prostate or uterus or vagina</li>
                            <li><strong>T4b</strong>: Tumour invades pelvic wall or abdominal wall</li>
                          </ul>
                          <p>The suffix "m" should be added to the appropriate T category to indicate multiple tumours. The suffix "is" may be added to any T to indicate the presence of associated carcinoma in situ</p>
                          <h4>Regional lymph nodes (N)</h4>
                          <ul>
                            <li><strong>NX</strong>: Regional lymph nodes cannot be assessed</li>
                            <li><strong>N0</strong>: No regional lymph-node metastasis</li>
                            <li><strong>N1</strong>: Metastases in a single lymph node, 2 cm or less in greatest dimension</li>
                            <li><strong>N2</strong>: Metastases in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension</li>
                            <li><strong>N3</strong>: Metastasis in a lymph node more than 5 cm in greatest dimension</li>
                          </ul>
                          <h4>Distant metastasis (M)</h4>
                          <ul>
                            <li><strong>MX</strong>: Distant metastasis cannot be assessed</li>
                            <li><strong>M0</strong>: No distant metastasis</li>
                            <li><strong>M1</strong>: Distant metastasis</li>
                          </ul>
                            
                        </p>
                      </div>


                                  <!-- image here -->
            <div class="image-container">
              <img src="../figures/urinary-tract-tumors (4).jpg" alt="" onclick="openModal(this)">
              <div class="caption">Staging</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">Staging</div>
            </div>
                     
            
            <h4>Spread</h4>

            <ul>
                <li><b>Direct:</b> En block (60%), Tentacular invasion (25%), lateral (10%)</li>
                <li><b>Lymphatic</b></li>
                <li><b>Vascular</b></li>
                <li><b>Implantation</b></li>
            </ul>
            
            <h4>Clinical Presentation</h4>
            
            <ul>
                <li>Hematuria</li>
                <li>Irritative LUTS</li>
                <li>Suprapubic pain</li>
                <li>Urinary tract obstruction</li>
                <li>Weight loss</li>
                <li>Bone pain</li>
                <li>Past Medical history</li>
                <li>Drugs</li>
                <li>Social history</li>
                <li>Examination findings</li>
                <li>Bimanual Examination</li>
            </ul>
            

            
            <h4>Differential Diagnosis</h4>
            
            <ul>
              <li>Bladder dysfunction (diabetes)</li>
              <ul>
                <li>Myogenic</li>
                <li>Neurogenic</li>
              </ul>

              <li>Extrinsic pelvic mass</li>
              <li>Cystitis</li>
              <li>Cystolithiasis</li>
              <li>Hypertrophy or stenosis of bladder neck</li>
              <li>BPH</li>
              <li>Prostate Cancer</li>
              <li>Vesicosphincter dyssynergia</li>
              <li>Urethral stricture</li>
              <li>Urethritis</li>
              <li>Stenosis of urinary meatus</li>
              <li>Urethral carcinoma</li>
            </ul>

            <h4>Investigations</h4>

            <ul>
                <li><b>Cystoscopy + Biopsy</b></li>
                <li><b>Urine Cytology</b></li>
                <li><b>Imaging</b>
                    <ul>
                        <li>Transabdominal USS</li>
                        <li>CT Urography</li>
                        <li>MRI</li>
                        <li>IVU</li>
                        <li>IVP</li>
                        <li>MR Virtual Cystoscopy</li>
                        <li>CXR</li>
                        <li>PET</li>
                        <li>Bone Scan</li>
                    </ul>
                </li>
                <li><b>Others</b>
                    <ul>
                        <li>FBC</li>
                        <li>E, U + Cr</li>
                        <li>LFT</li>
                        <li>PT/PTTK/INR</li>
                        <li>Urinalysis</li>
                        <li>Urine M/C/S</li>
                    </ul>
                </li>
            </ul>
            

            <h4>Treatment</h4>

            <p>Treatment of bladder cancer is multimodal and determined by the patient‚Äôs prognostic factors.</p>
            
            <h4>Treatment Categories:</h4>
            <ul>
                <li><b>NMIBC (Non-Muscle-Invasive Bladder Cancer)</b></li>
                <li><b>MIBC (Muscle-Invasive Bladder Cancer)</b></li>
                <li><b>METASTATIC BLADDER CANCER</b></li>
            </ul>
            

            <h4>NMIBC (CIS, Ta, T1) - 75%</h4>

            <ul>
                <li><b>CIS:</b> 40-83% will develop MIBC if not treated</li>
                <li><b>Focal:</b>
                    <ul>
                        <li>Intravesical therapy (MT-C, Thiotepa, Doxorubicin)</li>
                    </ul>
                </li>
                <li><b>Diffuse:</b>
                    <ul>
                        <li>BCG Immunotherapy (AUA, preference)</li>
                        <li>Early Cystectomy</li>
                        <li>BCG Immunotherapy followed by cystectomy</li>
                    </ul>
                </li>
            </ul>
            
            <h4>NMIBC</h4>
            
            <ul>
                <li><b>Aim of treatment:</b> To prevent recurrence and decrease progression to MIBC</li>
                <li>Currently, no role of radiotherapy</li>
                <li><b>Current Treatment Options:</b>
                    <ul>
                        <li>TURBT + Intravesical Immunotherapy</li>
                        <li>TURBT + Intravesical Chemotherapy</li>
                        <li>TURBT</li>
                        <li>LASER</li>
                        <li>Photodynamic Therapy</li>
                        <li>Thermochemotherapy</li>
                        <li>Nanotherapy</li>
                    </ul>
                </li>
            </ul>
            

            <h4>MIBC (T2-T4a, N0, M0) - 20%</h4>

            <ul>
                <li><b>85%</b> of patients will die by 2 years if left untreated.</li>
                <li>Aim of treatment is curative</li>
                <li>Radical cystectomy + PLND + Urinary reconstruction is the gold standard</li>
                <li>Currently, bladder preservation is increasingly being advocated</li>
                <h4>Treatment Options:</h4>
            
                <ul>
                    <li><b>Radical Cystectomy</b>
                        <ul>
                            <li>Cystoprostatectomy</li>
                            <li>Cystoprostatourethrectomy</li>
                            <li>Prostate sparing Cystectomy</li>
                            <li>Nerve Sparing Radical Cystectomy</li>
                            <li>Anterior Exenteration (Females)</li>
                        </ul>
                    </li>
                    <li><b>Radical Radiotherapy</b></li>
                    <li><b>Chemoradiotherapy</b></li>
                    <li><b>Chemotherapy</b></li>
                </ul>
            </ul>
            

            <h4>Metastatic Bladder Cancer</h4>

            <p>Options of treatment</p>
            <p><b>Aim:</b> Palliative</p>
            
            <ul>
                <li>Palliative Chemotherapy (gold standard)</li>
                <li>Palliative Radiotherapy</li>
                <li>Intracavitary Hyperthermic Perfusion Chemotherapy (ICHP)</li>
                <li>Molecular Targeted Therapy</li>
                <li>Targeted Therapy + Chemotherapy</li>
                <li>Molecular Targeted Photoimmunotherapy (MTP)</li>
            </ul>
            

            <h4>Complications</h4>

            <p><b>Disease and Treatment related</b></p>
            
            <ul>
                <li><b>TURBT:</b> UTI, bleeding, bladder perforation, urethral stricture, ureteral stenosis</li>
                <li><b>Cystectomy:</b> excessive primary hemorrhage, urinary leak, reflux of infected urine, urinary retention, SSI, DVT, impotence</li>
                <li><b>BCG:</b> Irritative LUTS, fever, hematuria, granulomatous prostatitis, epididymitis, arthralgia</li>
                <li><b>Chemotherapy:</b> Myelosuppression, cystitis, irritative LUTS, dystrophic calcification, etc.</li>
            </ul>
            
            <p><b>Radiotherapy:</b></p>
            <ul>
                <li><b>Acute:</b> Irritative LUTS, diarrhea</li>
                <li><b>Late:</b> Chronic irritative cystitis, hemorrhagic cystitis, bladder contracture, rectal stricture, small bowel obstruction</li>
            </ul>
            

            <h4>Prognosis</h4>

            <p><b>Multifactorial</b></p>
            
            <h5>Genetic</h5>
            <ul>
                <li>Alterations in TP53, RB, PTEN</li>
            </ul>
            
            <h5>Pathologic</h5>
            <ul>
                <li>Grade</li>
                <li>Presence of CIS</li>
                <li>Angiolymphatic invasion</li>
                <li>Proliferation markers: MIB-1, PCNA</li>
                <li>Depth of invasion</li>
            </ul>
            
            <h5>Clinical</h5>
            <ul>
                <li>Stage (most important determinant of survival)</li>
                <li>Metastasis</li>
                <li>Nodal disease</li>
                <li>Multifocality</li>
                <li>Rapidly recurring tumors</li>
                <li>Larger tumor size</li>
                <li>Presence of hydronephrosis</li>
                <li>Nodular or sessile tumors</li>
                <li>Residual disease</li>
                <li>Incomplete response to chemotherapy</li>
            </ul>
            

            <h4>Bladder Cancer Prevention</h4>
            <ul>
              <h4>Modification of risk factors</h4>
              <ul>
                <li>Stopping smoking</li>
                <li>Avoiding exposure to disinfection byproducts, artificial sweeteners, arsenic, industrial carcinogens, hair dyes, Chinese herb Aristolochia fangchi, etc.</li>
                <li>Avoiding urinary tract infection</li>
                <li>Avoiding treatments with radiation, phenacetin, or cyclophosphamide</li>
                <li>Drinking more water</li>
                <li>Inhibiting aging</li>
              </ul>
              
              <h4>Improvement of diagnosis and treatment protocols</h4>
              <ul>
                <li>Using 5-ALA-fluorescent cystoscopy</li>
                <li>Performing second TURBT</li>
                <li>Administering a single intravesical chemotherapy immediately after TURBT</li>
                <li>Improving intravesical BCG therapy</li>
              </ul>
              
              <h4>The use of nutraceuticals</h4>
              <ul>
                <li>Intake of vitamin A, B6, D, and E as well as mega-doses multivitamins</li>
                <li>Consuming plant products, such as soy, green tea, garlic, dietary isothiocyanates, mushroom extracts, silymarin, kava root extracts, etc.</li>
                <li>Using Lactobacillus probiotics</li>
                <li>Supplementation with selenium</li>
                <li>Intake of omega-3 fatty acids</li>
              </ul>
            </ul>


        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Prostate Tumours</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
              <li><b>BPH</b></li>
              <li><b>Malignant</b>
                  <ul>
                      <li><b>Adenocarcinoma</b></li>
                      <li><b>Sarcoma</b></li>
                      <li><b>Lymphoma</b></li>
                  </ul>
              </li>
          </ul>
          

          <section id='heading-4-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-1'>BPH</a>
              </h3>
            </header>
            <div class='body'>

              <ul>
                  <li><b>Histological BPH</b> represents an inescapable phenomenon for the aging male population.</li>
                  <li>Approximately <b>90% of men</b> will develop histologic evidence of BPH by <b>80 years of age</b>.</li>
                  <li>Significant problem due to the aging population and associated cost of treatment.</li>
                  <li><b>50% of men</b> will develop BPH.</li>
                  <li><b>50% of these</b> will develop bothersome LUTS.</li>
                  <li>Prevalence in middle-aged and elderly men: <b>11-65%</b></li>
                  <li>BPH is not life-threatening but interferes with quality of life.</li>
              </ul>
              
              <h4>Pathology</h4>
              <ul>
                  <li>BPH is nodular hyperplasia and not diffuse hyperplasia.</li>
                  <li>Affects the transitional and periurethral zones of the prostate.</li>
                  <li>Increase in cell number caused by epithelial and stromal proliferation or impaired programmed cell death leading to cellular accumulation.</li>
                  <li>Often the hyperplasia is multinodular, coalescing to form adenomata.</li>
                  <li>Adenomata from the transitional zone form the lateral lobes while adenomata from the periurethral zone form the middle lobe.</li>
              </ul>
              
                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/urinary-tract-tumors (5).jpg" alt="" onclick="openModal(this)">
              <div class="caption">BPH</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">BPH</div>
            </div>
            </div>

            <h4>Aetiology</h4>
            <ul>
                <li><b>Age</b></li>
                <li><b>Androgen</b></li>
                <li><b>Family history</b></li>
                <li><b>Ethnicity</b></li>
                <li><b>Lifestyle</b></li>
            </ul>
            
            <h4>Pathophysiology of BPH</h4>
            <ul>
                <li>The pathophysiology of bladder outlet obstruction in men with BPH has been attributed to both <b>static and dynamic factors</b>.</li>
                <li>Prostatic hyperplasia increases urethral resistance, resulting in compensatory changes in bladder function.</li>
                <li>Obstruction-induced changes in detrusor function, compounded by age-related changes in both bladder and nervous system function, lead to <b>urinary frequency, urgency, and nocturia</b>.</li>
            </ul>
            
            <ul>
                <li><b>BPH</b>
                    <ul>
                        <li>Enlarged prostate</li>
                        <li>Restricting capsule (in humans)</li>
                        <li>Pressure on prostatic urethra and bladder neck</li>
                        <li>Increased Urethral resistance</li>
                        <li><b>OBSTRUCTION!</b></li>
                    </ul>
                </li>
                <li><b>Obstruction</b>
                    <ul>
                        <li>Bladder compensation</li>
                        <li>Bladder decompensation</li>
                        <li>Increasing Residual Urine</li>
                        <li>Vesico-ureteric reflux (high bladder pressure, stretched trigone)</li>
                        <li>Upper tract obstruction and dilatation</li>
                        <li>Obstructive Uropathy</li>
                    </ul>
                </li>
            </ul>

            <h4>Clinical Presentation</h4>
            <ul>
                <li><b>Asymptomatic</b></li>
                <li><b>LUTS</b></li>
                <li><b>Urinary Retention</b></li>
                <li><b>Hematuria</b></li>
            </ul>
            
            <h4>Clinical Presentation (History)</h4>
            <ul>
                <li><b>Age</b></li>
                <li><b>LUTS</b></li>
                <li>Rule out differentials</li>
                <li><b>USDx</b></li>
                <li><b>CaP</b></li>
                <li>Polyuria ‚Äì <b>DM/diuretics</b></li>
                <li><b>Complications</b></li>
                <ul>
                    <li><b>Hematuria</b></li>
                    <li><b>CKD</b></li>
                    <li>Recurrent UTI</li>
                    <li>Hernia</li>
                </ul>
                <li>Medical and drug history</li>
                <li>Social history</li>
                <li><b>E.D.</b></li>
                <li><b>Infertility</b></li>
                <li>ROS for comorbidities</li>
            </ul>
            
            <h4>CNS Exam</h4>
            <ul>
                <li>Higher mental function</li>
                <li><b>Abd</b>
                    <ul>
                        <li>Hernia</li>
                        <li>Suprapubic swelling</li>
                        <li>Previous scars</li>
                    </ul>
                </li>
                <li>UGS: meatal stenosis, urethral mass</li>
                <li><b>RE</b>
                    <ul>
                        <li>Prostate size</li>
                        <li>Nodularity</li>
                        <li>Overlying rectal mucosa</li>
                    </ul>
                </li>
                <li>Other systems for comorbidities</li>
            </ul>
            

            <h4>Investigation</h4>
            <ul>
                <li><b>Imaging</b>
                    <ul>
                        <li>Trans Abdominal USS & TRUSS</li>
                        <li>CT Urogram</li>
                    </ul>
                </li>
                <li><b>Urinalysis</b></li>
                <li>Voiding Diary (frequency ‚Äì volume chart)</li>
                <li><b>Cystoscopy</b></li>
                <li><b>Urodynamic studies</b></li>
                <li><b>Rule Out Differentials</b>
                    <ul>
                        <li>PSA</li>
                        <li>Prostate Biopsy</li>
                    </ul>
                </li>
                <li><b>Ancillary</b>
                    <ul>
                        <li>EUCr</li>
                        <li>FBC</li>
                        <li>Clotting profile</li>
                        <li>GXM</li>
                    </ul>
                </li>
            </ul>
            
                        <!-- image here -->
                        <div class="image-container">
                          <img src="../figures/urinary-tract-tumors (6).jpg" alt="" onclick="openModal(this)">
                          <div class="caption">Questionnaire for International Prostate Symptoms Score</div>
                        </div>
                        
                        <div id="myModal" class="modal">
                          <span class="close" onclick="closeModal()">&times;</span>
                          <img class="modal-content" id="modalImage">
                          <div id="caption" class="caption">Questionnaire for International Prostate Symptoms Score</div>
                        </div>



                                    <!-- image here -->
            <div class="image-container">
              <img src="../figures/urinary-tract-tumors (7).jpg" alt="" onclick="openModal(this)">
              <div class="caption">Management Approach</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">Management Approach</div>
            </div>

            <h4>Management Options</h4>
            <ul>
                <li><b>Non-pharmacological measures</b>
                    <ul>
                        <li>Reducing nocturnal water intake</li>
                        <li>Reducing caffeine and alcohol consumption</li>
                        <li>Avoiding the use of decongestants and antihistamines</li>
                    </ul>
                </li>
                <li>Watchful waiting for patients with <b>IPSS score 0-7</b>, minimal impact on quality of life.</li>
                <li>Active monitoring requiring annual reevaluation.</li>
                <li><b>Phytotherapy</b>
                    <ul>
                        <li>Pollen extract and the leaves of Saw palmetto berry (<i>Serenoa repens</i>)</li>
                        <li>Bark of <i>Pygeum africanum</i></li>
                        <li>Roots of <i>Echinacea purpurea</i> and <i>Hypoxis rooperi</i></li>
                    </ul>
                </li>
            </ul>
            
            <h4>Pharmacologic</h4>
            <ul>
                <li><b>Alpha blockers</b></li>
                <li><b>5-alpha reductase inhibitors</b></li>
                <li>Anticholinergic drugs</li>
                <li>Antimuscarinic drugs</li>
                <li>Phosphodiesterase-5 inhibitors</li>
                <li>Beta-3 agonist</li>
            </ul>
            
            <h4>Indications for Surgery</h4>
            <ul>
                <li>Urinary retention refractory to medical management (and TWOC)</li>
                <li>Recurrent urinary tract infection</li>
                <li>Recurrent gross hematuria</li>
                <li>Bladder stones</li>
                <li>Renal insufficiency</li>
                <li>Large bladder diverticula</li>
            </ul>
            
            <h4>Operative</h4>
            <ul>
                <li><b>Minimally Invasive Therapies</b>
                    <ul>
                        <li>Transurethral needle ablation (TUNA)</li>
                        <li>Transurethral microwave heat treatments (TUMT)</li>
                    </ul>
                </li>
                <li><b>Surgical Therapies</b>
                    <ul>
                        <li>Open prostatectomy</li>
                        <li>Transurethral holmium laser ablation of the prostate (HoLAP)</li>
                        <li>Transurethral holmium laser enucleation of the prostate (HoLEP)</li>
                        <li>Holmium laser resection of the prostate (HoLRP)</li>
                        <li>Photoselective vaporization of the prostate (PVP)</li>
                        <li>Transurethral incision of the prostate (TUIP)</li>
                        <li>Transurethral vaporization of the prostate (TUVP)</li>
                        <li>Transurethral resection of the prostate (TURP)</li>
                    </ul>
                </li>
            </ul>

            <h4>Complications</h4>
            <ul>
                <li><b>Due to Disease</b>
                    <ul>
                        <li>Bladder decompensation</li>
                        <li>UTI</li>
                        <li>Bladder stones</li>
                        <li>Hernia</li>
                        <li>Azotemia</li>
                        <li>Hematuria</li>
                        <li>AUR</li>
                    </ul>
                </li>
                <li><b>Due to Intervention</b>
                    <ul>
                        <li>Erectile dysfunction</li>
                        <li>Retrograde Ejaculation</li>
                        <li>Drugs</li>
                        <li>Hypotension</li>
                        <li>TURP</li>
                        <li>TURP syndrome</li>
                        <li>Incontinence</li>
                        <li>Prostatectomy</li>
                        <li>Bleeding</li>
                        <li>Bladder neck stenosis</li>
                    </ul>
                </li>
            </ul>
            

          </section>

          <section id='heading-4-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-2'>Prostate Cancer</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                  <li>Most common cancer in men, and 2nd greatest cause of cancer mortality in men</li>
                  <li>Disease awareness has grown in the past 2 decades</li>
                  <li>Currently, <b>1 in 6 men</b> will be diagnosed with CAP</li>
                  <li><b>PSA</b> playing a role in detection and follow-up</li>
              </ul>
              
              <h4>Carcinoma of the Prostate</h4>
              <p>Most common malignancy in males after middle age</p>
              <ul>
                  <li>In western countries lifetime risk of microscopic prostate cancer: <b>30%</b></li>
                  <li>Uncommon before <b>50 years</b> Post mortem:
                      <ul>
                          <li><b>14%</b> of all males over <b>50 years</b></li>
                          <li><b>80%</b> of all males over <b>70 years</b></li>
                      </ul>
                  </li>
                  <li>No geographical or racial difference in incidence of post-mortem</li>
              </ul>
              
              <h4>Risk Factors</h4>
              <ul>
                  <li>Not well known</li>
                  <li>Hereditary - One <b>1st line relative</b> ‚Äì Risk doubles</li>
                  <li><b>2 or more 1st line relatives</b> ‚Äì risk x 10 True hereditary Ca-P (9%) ‚Äì 3 or more relatives involved or at least 2 with early Staged disease (i.e. <b>< 55 yrs</b>).</li>
                  <li>Race
                      <ul>
                          <li>Highest in <b>Negroes</b></li>
                          <li>Least in the <b>Orients</b></li>
                      </ul>
                  </li>
              </ul>
              
              <h4>Histological Types</h4>
              <ol>
                  <li>Adenocarcinoma ‚Äì&gt; <b>90%</b>
                      <ul>
                          <li>Conventional ‚Äì Majority of cases</li>
                          <li>Mucinous</li>
                          <li>Neuroendocrine</li>
                          <li>Small cell</li>
                      </ul>
                  </li>
                  <li>Transitional ‚Äì usually from the prostatic urethra.</li>
                  <li>Squamous cell</li>
                  <li>Sarcoma</li>
                  <li>Lymphomas</li>
              </ol>
              <p>2-5 Above do not produce <b>PSA</b></p>
              

              <h4>Staging and Grading</h4>
              <p><b>Staging - TNM</b></p>
              <p><b>Grading - Gleason score</b> (2-10)</p>
              <p><b>Gleason grade</b> (1‚Äì5)</p>
              <p>2 - least aggressive<br>
              10 - most aggressive</p>
              <p>Spread ‚Äì Local, Blood, Lymphatics</p>
              <ul>
                  <li><b>Local</b> ‚Äì Prostatic urethra, bladder, seminal vesicles.</li>
                  <li><b>Blood</b> ‚Äì Hips, vertebrae</li>
                  <ul>
                    <li>Ca ‚Äì P commonest site of bony metastasis, followed by breast, kidney, bronchus, thyroid.</li>
                    <li>Ca ‚Äì P metastasize early to the vertebrae because of the valveless vein of Batson that connects with the vertebral veinous plexus.</li>
                  </ul>
              </ul>
              
              <h4>Diagnosis / Clinical Staging</h4>
              <p><b>Clinical Features</b></p>
              <ol>
                  <li>Asymptomatic ‚Äì From routine screening, PSA, DRE, TRUSS</li>
                  <li>Local disease ‚Äì Lower urinary tract symptoms Obstructive, Irritative</li>
                  <li>Local Invasion ‚Äì Urethra ‚Äì Haematuria, dysuria Trigone ‚Äì hydroureters, hydronephrosis Pelvic nerves ‚Äì pain, erectile dysfunction Rectum ‚Äì Bleeding, constipation</li>
                  <li>Metastatic Disease
                      <ul>
                          <li>Vertebrae - Low back pain</li>
                          <li>Pathological fractures</li>
                          <li>Lymphnode enlargement ‚Äì Lower limb edema</li>
                          <li>Cerebral metastases</li>
                          <li>Skin</li>
                          <li>Liver, lungs etc</li>
                      </ul>
                  </li>
              </ol>
              

              <h4>DRE</h4>
              <ul>
                  <li>Gland may be normal</li>
                  <li><b>Hard nodule</b> ‚Äì hallmark</li>
                  <li>Asymmetric enlargement</li>
                  <li>Heterogeneous consistency ‚Äì hard, soft, firm areas.</li>
                  <li>Distorted or absent median sulcus</li>
                  <li>Involvement of lateral structures - winging.</li>
                  <li>Palpable seminal vesicles</li>
                  <li>Adherence of rectal mucosa</li>
              </ul>
              
              <h4>PSA</h4>
              <ul>
                  <li>Organ specific but not disease specific.</li>
                  <li>Most likely responsible for the stage migration.</li>
                  <li>No universally accepted value. Recommended values:
                      <ul>
                          <li>Total - <b>&lt; 4ng/ml</b>; 4 ‚Äì 10 ng/ml, &gt; 10ng/ml</li>
                          <li>Free / Total - Very useful in patients with PSA between 4 ‚Äì 10</li>
                          <li>0.15 ‚Äì Recommended, PPV = 76%</li>
                          <li>The lower the f/t PSA, the greater the risk of cancer</li>
                      </ul>
                  </li>
                  <li><b>PSA Density</b> - Takes care of overlap between Ca-P & BPH. Recommended value - &gt; 0.15 highly suggestive of Ca ‚Äì P.</li>
                  <li><b>PSA Velocity</b> - Rate of change of PSA with time.
                      <ul>
                          <li>At least 3 measurements within 2 years.</li>
                          <li>&gt; 0.75 ng/ml ‚Äì suggestive of Ca ‚ÄìP.</li>
                      </ul>
                  </li>
                  <li><b>Age Specific PSA:</b>
                      <ul>
                          <li>sensitivity in younger men</li>
                          <li>specificity in older men</li>
                          <li>40 ‚Äì 49 ‚Äì <b>2.5 ng/ml</b></li>
                          <li>50 ‚Äì 59 ‚Äì <b>3.5 ng/ml</b></li>
                          <li>60 ‚Äì 69 ‚Äì <b>4.5 ng/ml</b></li>
                          <li>70 ‚Äì 79 ‚Äì <b>6.5 ng/ml</b></li>
                      </ul>
                  </li>
                  <li><b>PSA Doubling Time</b>
                      <ul>
                          <li>Useful in differentiating local recurrence from metastatic disease in patients previously treated for early Ca ‚Äì P.</li>
                          <li>&lt; 6 months ‚Äì Metastases</li>
                          <li>&gt; 6 months ‚Äì Local recurrence</li>
                      </ul>
                  </li>
              </ul>
              
              <h4>Trans Rectal Ultrasound (TRUS)</h4>
              <ul>
                  <li><b>Classic Feature:</b> Hypoechogenic area in peripheral zone.</li>
                  <li>Hyperechogenic / Normoechogenic lesions Are also common</li>
                  <li>Not very useful in direct screening</li>
                  <li>Main use in needle biopsy.</li>
              </ul>
              
              <h4>Prostate Biopsy</h4>
              <ol>
                  <li>Digitally guided FNAB</li>
                  <li>TRUSS guided transrectal core needle biopsy - gold standard.
                      <ul>
                          <li>Sextant to 12 cores recommended.</li>
                          <li>The greater the number of cores, the greater the success rate.</li>
                      </ul>
                  </li>
              </ol>

              
              <h4>Treatment</h4>
              <p>Natural History ‚Äì <b>75%</b> of men with diagnosis of Ca-P without treatment will die from the Disease.</p>
              <p><b>LOCALISED DISEASE:</b> T1 ‚Äì T2m No MO.</p>
              <ol>
                  <li><b>Watchful Waiting</b> ‚Äì Ideal for an asymptomatic man, life expectancy <10 yrs, low Gleason score. Evidence suggests greater risk of death from Ca-P when compared with treated groups.</li>
                  <li><b>Radiation Therapy</b>
                      <ul>
                          <li><b>External beam:</b> Outcome almost as good as surgery. Contraindicated in patients with colo-rectal disease and bladder outlet obstruction. 3D conformal radiotherapy ‚Äì Now gold standard.</li>
                          <li><b>Brachytherapy:</b> In very small tumors. Cure difficult to assess since tumor cells die gradually. Positive biopsies may not indicate failure, likewise a high PSA. Late toxicity eg bladder, erectile, bowel problems years after therapy.</li>
                      </ul>
                  </li>
                  <li><b>Radical Prostatectomy</b>
                      <ul>
                          <li>Gold standard. Retropubic or Transperineal or laparoscopic.</li>
                          <li>Not indicated in patients with short life expectancy.</li>
                          <li>Prostate gland including the capsule, Periprostatic fascia, ejaculatory duct, seminal vesicles and prostatic urethra. Walsh nerve sparing technique - lower risk of erectile dysfunction.</li>
                          <li>Bleeding, Incontinence, Erectile dysfunction, Urethral stricture, rectal injury.</li>
                      </ul>
                  </li>
                  <li><b>Others</b>
                      <ul>
                          <li><b>Cryo Surgery</b> - Less bleeding, Similar complications as RP</li>
                          <li><b>High Intensity Focused Ultrasound (HIFU)</b></li>
                          <li><b>LASER</b></li>
                          <li><b>Hormonal Manipulation</b> ‚Äì Occasional patient who declines radical therapy or unfit for radical therapy.</li>
                      </ul>
                  </li>
              </ol>
              
              <h4>Advanced Disease</h4>
              <p><b>Hormonal Manipulation</b> ‚Äì Gold standard</p>
              <ul>
                  <li>Elimination of testicular testosterone</li>
                  <li>Eliminates > 90% of circulating testosterone.
                      <ul>
                          <li><b>Bilateral orchidectomy</b> ‚Äì Gold Standard</li>
                          <li><b>LHRH agonist</b> - Like above. Expensive. Flare phenomenon ‚Äì Use antiandrogen for first 6 weeks. Never use alone in patients with impending paraplegia</li>
                          <li>Andropause ‚Äì main side effect: impotence, loss of libido, less muscle bulk and bone density, hot flushes, etc.</li>
                      </ul>
                  </li>
              </ul>
              
              <p><b>Oestrogens</b> ‚Äì Mechanism - reduce LHRH secretion, direct reduction in Leydig cell function, and direct androgen inactivation.</p>
              <ul>
                  <li>Diethylstilbestrol ‚Äì Inexpensive, significant CVS morbidity. 1mg-5mg</li>
                  <li>Phosphorylated form ‚Äì less toxicity</li>
              </ul>
              
              <p><b>LHRH Antagonist</b> ‚Äì No flare phenomenon. Rapidly acting. Lack of depo preparation delayed clinical introduction. Depo forms now available. Soon to replace LHRH agonists</p>
              
              <p><b>Antiandrogens</b> ‚Äì Compete with androgen at the receptor level. Inferior to orchidectomy as monotherapy</p>
              <ul>
                  <li>Non-steroidal ‚Äì Flutamide, bicalutamide. Less effect on Libido.</li>
                  <li>Steroidal ‚Äì Cyproterone acetate ‚Äì Greater side effect on Libido. Expensive. Less effective than orchidectomy.</li>
              </ul>
              
              <p><b>Progestogens</b> ‚Äì Medroxyprogesterone acetate.</p>
              
              <h4>Maximal Androgen Blockade (MAB)</h4>
              <p>Combination of orchidectomy (or LHRH agonist or oestrogen) and antiandrogens.</p>
              <ul>
                  <li>Blocks both testicular and extratesticular androgens.</li>
                  <li>Doubtful superiority over orchidectomy alone.</li>
              </ul>
              
              <h4>Minimal Androgen Blockade (MIB)</h4>
              <ul>
                  <li>Finasteride - 5 alpha-reductase inhibitor ‚Äì reduces intraprostatic DHT.</li>
                  <li>PLUS</li>
                  <li>Antiandrogen ‚Äì Competes with remaining DHT for receptors. Keeps serum testosterone normal, hence no side effects associated with testosterone.</li>
              </ul>
              

              <h4>Treatment Failure</h4>

              <p><b>For post RP & RR patient</b> ‚Äì defined as a rising PSA after treatment with curative intent.</p>
              <ul>
                  <li>Options - Individualized: RP, RR, Hormone manipulation or Watchful Waiting</li>
              </ul>
              
              <p><b>Hormone Refractory Disease</b> ‚Äì Invariably occurs in patients managed by androgen deprivation. Most patients die within 1 year.</p>
              
              <h4>Definition:</h4>
              <ol>
                  <li>Serum testosterone at castrate level.</li>
                  <li>3 consecutive rises in PSA 2 weeks apart.</li>
                  <li>Antiandrogen withdrawal for at least 4 weeks.</li>
                  <li>PSA progression despite secondary hormonal manipulations.</li>
                  <li>Progress of osseous or soft tissue lesions.</li>
              </ol>
              
              <h4>Options:</h4>
              <ol>
                  <li>Give antiandrogens ‚Äì if not initially given</li>
                  <li>Withdraw antiandrogens.</li>
                  <li>High dose antiandrogens</li>
                  <li>Oestrogens ‚Äì Estramustine</li>
                  <li>Ketoconazole</li>
                  <li>Aminoglutethimide</li>
                  <li>Strontium-89 - Bone metastases</li>
                  <li>Bisphosphonates - bone metastases</li>
                  <li>Hemibody radiation</li>
                  <li>Docetaxel therapy</li>
                  <li>Mitoxantrone</li>
                  <li>Steroids</li>
                  <li>Supportive care</li>
              </ol>
              

              <h4>Prevention / Screening</h4>
              <ol>
                  <li><b>PSA / DRE / TRUSS</b></li>
                  <li><b>Diet</b> - Vitamin D, Selenium, fat intake</li>
                  <li><b>Chemoprevention</b> ‚Äì Finasteride for high-risk groups</li>
              </ol>
              
            </div>
          </section>

          <section id='heading-4-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-3'>Ureteric Tumours</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                  <li>Rare</li>
                  <li>Most are malignant</li>
                  <li>Transitional cell carcinoma usually</li>
                  <li><b>Risk factor:</b> smoking</li>
                  <li>Mostly presenting with hematuria</li>
                  <li><b>Diagnosis:</b> IVP, Ureteroscopy + biopsy, CT Urography</li>
                  <li><b>Treatment:</b> Surgery (Nephroureterectomy), Chemotherapy, Radiotherapy</li>
              </ul>
              

            </div>
          </section>
        </div>
      </section>








      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>


      </div>

       

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>

        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
